Skip to content
DataLookout
Menu

NCT07645287

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 55 → 59 locations
  2. Notable Eligibility criteria expanded, about 7 words Show 4 more changesShow less
    • Primary endpoints: details revised at 2 of 2 entries
    • Study sites: 55 to 57
    • Interventions: B/F/TAF (Drug), GS-3242 Injection (Drug), GS-3242 Tablet (Drug), Lenacapavir Injection (Drug), Lenacapavir Tablet (Drug) to B/F/TAF (Drug), GS-3242 Injection (Drug), GS-3242 Tablet (Drug), Lenacapavir Injection (Drug), Lenacapavir Tablet (Drug)
    • Secondary endpoints: details revised at 4 of 14 entries
  3. Minor Trial sites expanded: 36 → 55 locationsv4
  4. Minor Trial sites expanded: 3 → 36 locationsv3
  5. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jun 2026 to Jun 15, 2026
    • Secondary endpoints revised (14)
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part A: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Timeframe: Week 35
Part B: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm
Timeframe: Week 26

Secondary (14)

Part A and Part B: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the US FDA Snapshot Algorithm
Part A and Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Part A: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 35
Part A and Part B: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 52
Show 9 moreShow less
Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm
Part B: Change From Baseline in CD4 Cell Count at Week 26
Part A: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 35
Part A and Part B: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 52
Part B: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 26
Part A: Group 1 and 2:Trough Concentrations of GS-3242 and LEN at Week 18
Part A: Group 1 and 2:Trough Concentrations of GS-3242 and LEN at Week 35
Part A: Group 1 and 2 and Part B: Groups 1 and 2:Trough Concentrations of GS-3242 and LEN at Week 52
Part B: Trough Concentrations at GS-3242 and LEN at Week 26

Arms and interventions

Part A: Group 1 of GS-3242 + LENExperimental

Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN up to 52 weeks.

Part A: Group 2 of GS-3242 + LENExperimental

Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by a IM injections of GS-3242 (at a different dose than Group 1) and LEN up to 52 weeks.

Part A: Group 3 of B/F/TAFExperimental

Participants will be randomized to continue to receive 50/200/25 mg of B/F/TAF daily for up to 52 weeks.

Part B: Group 4 (Conditional) of GS-3242 + LENExperimental

Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injection of GS-3242 and LEN (at different doses than Groups 1 and 2) up to 52 weeks.

Drugs: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF

Sites

59 sites in 4 countries

United States 49, Australia 4, Canada 3, Puerto Rico 3